Open AccessPancreatoduodenectomy for Neuroendocrine Tumors in Patients with Multiple Endocrine Neoplasia Type 1: An AFCE (Association Francophone de Chirurgie Endocrinienne) and GTE (Groupe d’étude des Tumeurs Endocrines) Study
Author(s) -
Santucci Nicolas,
Gaujoux Sébastien,
Binquet Christine,
Reichling Cynthia,
Lifante JeanChristophe,
Carnaille Bruno,
Pattou François,
Mirallié Eric,
Facy Olivier,
Mathonnet Muriel,
Goudet Pierre
Publication year - 2021
Publication title -
world journal of surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.115
H-Index - 148
eISSN - 1432-2323
pISSN - 0364-2313
DOI - 10.1007/s00268-021-06005-7
Subject(s) - medicine , gastrinoma , multiple endocrine neoplasia , men1 , glucagonoma , neuroendocrine tumors , gastroenterology , insulinoma , abdominal surgery , zollinger ellison syndrome , endocrine system , hormone , gastrin , pancreas , biochemistry , chemistry , secretion , gene
Aim To assess postoperative complications and control of hormone secretions following pancreatoduodenectomy (PD) performed on multiple endocrine neoplasia type 1 (MEN1) patients with duodenopancreatic neuroendocrine tumors (DP‐NETs). Background The use of PD to treat MEN1 remains controversial, and evaluating the right place of PD in MEN1 disease makes sense. Methods Thirty‐one MEN1 patients from the Groupe d’étude des Tumeurs Endocrines MEN1 cohort who underwent PD for DP‐NETs between 1971 and 2013 were included. Early and late postoperative complications, secretory control and overall survival were analyzed. Results Indication for surgery was: Zollinger–Ellison syndrome ( n = 18; 58%), nonfunctioning tumor ( n = 9; 29%), insulinoma ( n = 2; 7%), VIPoma ( n = 1; 3%) and glucagonoma ( n = 1; 3%). Mean follow‐up was 141 months (range 0–433). Pancreatic fistulas occurred in 5 patients (16.1%), distant metastases in 6 (mean onset of 43 months; range 13–110 months), postoperative diabetes mellitus in 7 (22%), and pancreatic exocrine insufficiency in 6 (19%). Five‐year overall survival was 93.3% [CI 75.8–98.3] and ten‐year overall survival was 89.1% [CI 69.6–96.4]. After a mean follow‐up of 151 months (range 0–433), the biochemical cure rate for MEN‐1 related gastrinomas was 61%. Conclusion In MEN1 patients, pancreatoduodenectomy can be used to control hormone secretions (gastrin, glucagon, VIP) and to remove large NETs. PD was found to control gastrin secretions in about 60% of cases.